New MedPredict Report Reveals Top Alzheimer’s Experts’ Insights on Diagnostics and Treatments in Pipeline

Share Article

Do thought leaders prefer active or passive immunotherapy? Gamma-secretase inhibitors or Tau inhibitors? Neurology KOLs rank Alzheimer’s compounds in development to project future winners based on available clinical data.

The panel covers active and passive immunologic approaches and targeted therapies that will improve outcomes in the prevention and treatment of Alzheimer’s disease and mild cognitive impairment.

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Alzheimer’s Disease,” designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area.

MedPredict interviewed renowned Alzheimer’s disease thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs.

“In this report, our expert panel describes the clinical progress of the most interesting therapeutic and diagnostic candidates in the pipeline,” according to Jeff Berk, MedPredict’s president and lead author of this report. “The panel covers active and passive immunologic approaches and targeted therapies that will improve outcomes in the prevention and treatment of Alzheimer’s disease and mild cognitive impairment.”

MedPredict’s Thought Leader Panel ranks the most promising small molecules and antibodies that are targeting amyloid and plaques, offering their opinions on gamma-secretase inhibitors and modulators, beta-secretase inhibitors, Tau inhibitors, cardiovascular agents, anti-amyloids and aggregation inhibitors, mTOR inhibitors, SIRT-1, Liver X, metal chelators and drugs specifically designed to enhance mental function.

“Physicians who treat Alzheimer’s disease face multiple challenges in their effort to improve the lives of patients who have or will have dementia,” said Berk. “Just as a cardiologist would do to prevent a heart attack in a patient with high blood pressure and high cholesterol, the neurologist or gerontologist must be able to identify people who are at risk of developing mild cognitive impairment and progressing on to Alzheimer’s disease, and treat them prophylactically. For patients with more advanced disease, new therapies are needed to slow degeneration, enhance cognitive function and protect the remaining neuronal structure. For both symptomatic and asymptomatic patients, diagnostics are needed to track the effectiveness of these new therapeutics.”

Companies/partnerships discussed in this report: Abbott, Allon, Astellas/CoMentis, Ariad, AstraZeneca/Banner, AstraZeneca/Takeda, AstraZeneca, Avid, Baxter, Bayer-Schering/Avid, Boehringer Ingelheim/Ablynx, Bristol-Myers Squibb, Ceregene, Elan/Transition Therapeutics/AstraZeneca, Elan/Johnson & Johnson/Pfizer, Eisai, GE Healthcare, GlaxoSmithKline, Lilly, Lilly/Elan, Merck, Noscira/Zeltia, Novartis, Pfizer, Pfizer/Medivation, Prana, TauRx, and Transtech/Pfizer.

The full report may be purchased by contacting MedPredict.

About MedPredict
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.

For more information contact:
Elizabeth Mathews
MedPredict
513.271.1924
liz (at) medpredict (dot) com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Elizabeth Mathews
Visit website